Organon Canada, a global healthcare company with a mission to improve the health of women throughout their lives, today announced that Health Canada has approved NDUVRA (tapinarof cream), 1%, the first in a novel class of aryl hydrocarbon receptor agonists to be approved in Canada, for the topical treatment of plaque psoriasis in adults.1

"The approval of NDUVRA (tapinarof cream) introduces a new treatment option for adult patients with mild to severe plaque psoriasis. In clinical trials, patients who achieved complete disease clearance discontinued treatment and experienced a sustained median response for approximately four months," said Michael Casia, President and Managing Director, Organon Canada. "Organon Canada is pleased to expand its existing and growing dermatology portfolio through the addition of tapinarof, bringing a novel treatment option to the most common form of psoriasis.2"

The approval of NDUVRA is based on the results from two randomized, double-blind, multicenter, vehicle-controlled trials conducted to evaluate the safety and efficacy of tapinarof cream for the treatment of adults with plaque psoriasis (symptoms varying from mild to severe).

Tapinarof is a cream that is applied once daily to affected areas. It may be used on all skin surfaces, including the head, neck, and intertriginous areas.

Tapinarof, known as VTAMA® outside of Canada, became part of the Organon portfolio in October 2024 as part of the company's acquisition of Dermavant, with Canada representing the second country to approve the product worldwide.